160 related articles for article (PubMed ID: 37528464)
1. Novel agents and clinical trials in castration-resistant prostate cancer: latest updates from 2023 ASCO-GU Cancers Symposium.
Jiang Y; Wu S; Li R; Yu J; Zheng J; Li Z; Li M; Xin K; Xu Z; Li S; Chen X
Exp Hematol Oncol; 2023 Aug; 12(1):68. PubMed ID: 37528464
[TBL] [Abstract][Full Text] [Related]
2. Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium.
Yu J; Wu S; Li R; Jiang Y; Zheng J; Li Z; Li M; Xin K; Guan X; Li S; Chen X
J Hematol Oncol; 2023 Jul; 16(1):85. PubMed ID: 37507780
[TBL] [Abstract][Full Text] [Related]
3. Abrogation of HnRNP L enhances anti-PD-1 therapy efficacy
Zhou X; Zou L; Liao H; Luo J; Yang T; Wu J; Chen W; Wu K; Cen S; Lv D; Shu F; Yang Y; Li C; Li B; Mao X
Acta Pharm Sin B; 2022 Feb; 12(2):692-707. PubMed ID: 35256940
[TBL] [Abstract][Full Text] [Related]
4. Second-Line Hormonal Therapy for Men With Chemotherapy-Naïve, Castration-Resistant Prostate Cancer: American Society of Clinical Oncology Provisional Clinical Opinion.
Virgo KS; Basch E; Loblaw DA; Oliver TK; Rumble RB; Carducci MA; Nordquist L; Taplin ME; Winquist E; Singer EA
J Clin Oncol; 2017 Jun; 35(17):1952-1964. PubMed ID: 28441112
[TBL] [Abstract][Full Text] [Related]
5. The establishment of polypeptide PSMA-targeted chimeric antigen receptor-engineered natural killer cells for castration-resistant prostate cancer and the induction of ferroptosis-related cell death.
Wu L; Liu F; Yin L; Wang F; Shi H; Zhao Q; Yang F; Chen D; Dong X; Gu Y; Xing N
Cancer Commun (Lond); 2022 Aug; 42(8):768-783. PubMed ID: 35706368
[TBL] [Abstract][Full Text] [Related]
6. Genitourinary cancers updates: highlights from ASCO 2023.
Qin Q; Sheffield H; Taasan SM; Wang AZ; Zhang T
J Hematol Oncol; 2023 Nov; 16(1):112. PubMed ID: 37990343
[TBL] [Abstract][Full Text] [Related]
7. Inside prostate cancer news from the 2021 ASCO Genitourinary Cancers Symposium.
Iacovelli R; Astore S; Ciccarese C; Cannella MA; Bove P; Iacovelli V; Tortora G
Expert Rev Anticancer Ther; 2021 Nov; 21(11):1207-1210. PubMed ID: 34493147
[TBL] [Abstract][Full Text] [Related]
8. Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer.
Zarrabi KK; Narayan V; Mille PJ; Zibelman MR; Miron B; Bashir B; Kelly WK
Ther Adv Urol; 2023; 15():17562872231182219. PubMed ID: 37359737
[TBL] [Abstract][Full Text] [Related]
9. Inside the 2015 ASCO Genitourinary Cancers Symposium.
Santoni M; Massari F; Iacovelli R; Ciccarese C; Verri E; Burattini L; Montironi R; Nolè F; Tortora G; Cascinu S
Future Oncol; 2015; 11(13):1859-62. PubMed ID: 26161923
[TBL] [Abstract][Full Text] [Related]
10. Prospect of Prostate Cancer Treatment: Armed CAR-T or Combination Therapy.
Jiang Y; Wen W; Yang F; Han D; Zhang W; Qin W
Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205714
[TBL] [Abstract][Full Text] [Related]
11. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
12. Effective combinatorial immunotherapy for castration-resistant prostate cancer.
Lu X; Horner JW; Paul E; Shang X; Troncoso P; Deng P; Jiang S; Chang Q; Spring DJ; Sharma P; Zebala JA; Maeda DY; Wang YA; DePinho RA
Nature; 2017 Mar; 543(7647):728-732. PubMed ID: 28321130
[TBL] [Abstract][Full Text] [Related]
13. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y
Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of IL-6-JAK/Stat3 signaling in castration-resistant prostate cancer cells enhances the NK cell-mediated cytotoxicity via alteration of PD-L1/NKG2D ligand levels.
Xu L; Chen X; Shen M; Yang DR; Fang L; Weng G; Tsai Y; Keng PC; Chen Y; Lee SO
Mol Oncol; 2018 Mar; 12(3):269-286. PubMed ID: 28865178
[TBL] [Abstract][Full Text] [Related]
15. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
16. Inside the 2016 American Society of Clinical Oncology Genitourinary Cancers Symposium: part 2 - prostate and bladder cancer.
Buti S; Ciccarese C; Iacovelli R; Bersanelli M; Scarpelli M; Lopez-Beltran A; Cheng L; Montironi R; Tortora G; Massari F
Future Oncol; 2016 Sep; 12(17):1971-4. PubMed ID: 27312584
[TBL] [Abstract][Full Text] [Related]
17. Combination immunotherapy and radiotherapy causes an abscopal treatment response in a mouse model of castration resistant prostate cancer.
Dudzinski SO; Cameron BD; Wang J; Rathmell JC; Giorgio TD; Kirschner AN
J Immunother Cancer; 2019 Aug; 7(1):218. PubMed ID: 31412954
[TBL] [Abstract][Full Text] [Related]
18. Highlights from the 2024 ASCO Genitourinary Symposium: focus on urothelial and prostate cancer.
Strusi A; Pinterpe G; Ciccarese C; Pedone RR; Sarcina M; Sardaro V; Belletto R; Totaro A; Racioppi M; Berardi R; Tortora G; Iacovelli R
Expert Rev Anticancer Ther; 2024 Jun; ():1-4. PubMed ID: 38932631
[TBL] [Abstract][Full Text] [Related]
19. Generation of potent cytotoxic T lymphocytes against castration-resistant prostate cancer cells by dendritic cells loaded with dying allogeneic prostate cancer cells.
Hwang EC; Lim MS; Im CM; Kwon DD; Lee HJ; Nguyen-Pham TN; Lee YK; Lee JJ
Scand J Immunol; 2013 Feb; 77(2):117-24. PubMed ID: 23126536
[TBL] [Abstract][Full Text] [Related]
20. Selected news from the 2014 Genitourinary Cancers Symposium: translating novel strategies into clinical practice.
Bianconi M; Santoni M; Massari F; Faloppi L; Del Prete M; Giampieri R; Ciccarese C; Modena A; Tortora G; Scartozzi M; Cascinu S
Future Oncol; 2014 Nov; 10(14):2103-6. PubMed ID: 25471023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]